ライフサイエンスコーパス: antigenemia

1 e HIV-infected and screened for cryptococcal antigenemia.

2 , dual CMV-CTLs were not associated with CMV antigenemia.

3 ereas 18 had cleared both microfilaremia and antigenemia.

4 dictive values for the detection of CMV pp65 antigenemia.

5 treated preemptively for the first positive antigenemia.

6 given either at engraftment or for CMV pp65 antigenemia.

7 ing antibodies in plasma, and high levels of antigenemia.

8 odies; and had low or undetectable levels of antigenemia.

9 ed with clinically detectable HBV disease or antigenemia.

10 fferent levels of CMV virus load measured by antigenemia.

11 monkeys, 2 having delayed onset and peak of antigenemia.

12 to anticytomegalovirus therapy or low-level antigenemia.

13 specimens and a latex agglutination test for antigenemia.

14 s treatments were started following onset of antigenemia.

15 ng outcomes among patients with cryptococcal antigenemia.

16 nts with suspected asymptomatic cryptococcal antigenemia.

17 ssed the onset or level of chronic rotavirus antigenemia.

18 ee Plasma-Lyte resulted in positive serum GM antigenemia.

19 serum antibodies are essential for resolving antigenemia.

20 gs, confirming previous reports of rotavirus antigenemia.

21 ed by blood-borne microfilariae and filarial antigenemia.

22 sults in 30 (77%) of 39 episodes detected by antigenemia.

23 ecificity, and predictive values compared to antigenemia: 122 of 151 antigenemia-positive samples wer

24 V-coinfected; 135 had persistent HBV surface antigenemia, 1374 had resolved HBV infection, and 287 we

25 ood samples tested for cytomegalovirus (CMV) antigenemia, 18 (16.5%) were positive.

26 re also higher in subjects experiencing late antigenemia (2.4% vs 0.57%).

27 8.1-fold (95% CI, 1.9-35.2) with HBV surface antigenemia, 2.1-fold (95% CI, 1.3-3.3) with fewer than

28 was similar between symptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%; P =

29 those with HCV (3.4) or hepatitis B surface antigenemia (6.5).

30 Sixty-four individuals (58%) developed p24 antigenemia a median of 11.6 years after seroconversion.

31 nciclovir use, HLA matching, circulating CMV antigenemia, absolute CD4+ and CD8+ counts, and donor CM

32 or cytomegalovirus (CMV) by culture and pp65 antigenemia across four test sites.

33 gG was associated directly with cryptococcal antigenemia adjusted for CD4 count and antiretroviral th

34 2), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels

35 tigate how a lower prevalence threshold (<1% antigenemia [Ag] prevalence compared with <2% Ag prevale

36 isease before or during the first episode of antigenemia and 6 (5.3%) developed disease after discont

37 at is significantly more sensitive than pp65 antigenemia and blood cultures for detection of CMV in b

38 The percentage of positive antigenemia and CMV disease was 55 and 8%, respectively.

39 patients had persistently elevated levels of antigenemia and CMV DNA by PCR when resistance to gancic

40 were compared by cytomegalovirus (CMV) pp65 antigenemia and CMV infectivity on the day of sample col

41 A significant relationship between p24 antigenemia and death was nonsignificant after adjusting

42 ing the start of ganciclovir until highgrade antigenemia and discontinuing ganciclovir based on negat

43 videnced by marked reductions in viremia and antigenemia and HBV core antigen-positive hepatocytes.

44 ients, there was a corresponding increase in antigenemia and leukopenia.

45 B delta Sp1234 showed lower levels of plasma antigenemia and lower virus burdens; the other animal in

46 The relationship between filarial antigenemia and lymphatic pathology was investigated in

47 nts with neurologic-symptomatic cryptococcal antigenemia and negative CSF cryptococcal antigen (CrAg)

48 ts, there was a good association between the antigenemia and PCR assays.

49 rt demonstrating that clearance of rotavirus antigenemia and possibly viremia are mediated by multipl

50 d for at least 3 weeks or until negative CMV antigenemia and resumed only if antigenemia recurred.

51 with the evidence of the persistent SIV p27 antigenemia and SIVmac-induced disease.

52 tients were monitored posttransplantation by antigenemia and TaqMan CMV QPCR.

53 ulin antagonist, and monitored the effect on antigenemia and the patient's clinical response.RESULTSW

54 reactivation in 28 patients were detected by antigenemia and treated by antiviral drugs.

55 positive for CMV, 106 (97%) were positive by antigenemia, and 34 (31%) were positive by culture.

56 (PBMC), quantitate gene expression, measure antigenemia, and determine nitric oxide levels.

57 ncy and the CD4 count, human cytomegalovirus antigenemia, and other risk factors for adrenal insuffic

58 All results of CMV PCR and/or pp65 antigenemia, and pathological reports were reviewed.

59 ients (64%) became positive by PBL PCR, pp65 antigenemia, and plasma PCR.

60 s), the leukocyte fraction was tested by CMV antigenemia, and quantitative PCR was performed on plasm

61 s in CD4+ cell counts, the highest levels of antigenemia, and the greatest expression of viral RNA an

62 Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal

63 ecting CMV infection, but that the degree of antigenemia as expressed by the number of positive cells

64 We compared the antigenemia assay (AA) with tandem shell vial cultures (

65 ture and an established cytomegalovirus pp65 antigenemia assay (CMV AG).

66 o the eye examinations were 80% for the pp65 antigenemia assay (cutoff, >0 cell per 1.5 x 10(5) leuko

67 UL55/UL123-exon 4) were compared to the pp65 antigenemia assay and blood cultures.

68 Recent diagnostic advances, such as the CMV antigenemia assay and CMV-DNA detection by polymerase ch

69 OR CMV Test was compared to those of the CMV antigenemia assay and the conventional tube culture meth

70 lue were 70.5, 97.5, 87.8, and 92.8% for the antigenemia assay and were 96.7, 92.0, 75.6, and 99.1% f

71 In 49 specimens, PBL PCR and/or pp65 antigenemia assay could not be performed because of insu

72 Sens CMV pp67 tests were compared to the CMV antigenemia assay for 45 transplant recipients and 1 pat

73 MV) DNA in plasma is less sensitive than the antigenemia assay for CMV surveillance in blood.

74 requently in blood specimens than either the antigenemia assay or cultures, but of the three PCR assa

75 ective study, the cytomegalovirus (CMV) pp65 antigenemia assay was compared with detection of CMV by

76 CR assay, and the cytomegalovirus (CMV) pp65 antigenemia assay was evaluated in transplant recipients

77 V Test, 21 (19%) of the specimens by the CMV antigenemia assay, and 10 (9%) of the specimens by cultu

78 ral blood leukocytes (PBL PCR), the CMV pp65 antigenemia assay, and viral cultures from blood, urine,

79 assay (MTP-PCR) and a semiquantitative pp65 antigenemia assay, each specimen was measured for HCMV l

80 he most sensitive test, followed by the pp65 antigenemia assay, plasma PCR, and viremia.

81 nc.) were tested in the cytomegalovirus pp65 antigenemia assay, to determine if whole-blood processin

82 to those of the more technically cumbersome antigenemia assay.

83 t of PBL PCR but similar to that of the pp65 antigenemia assay.

84 underwent weekly surveillance using the pp65 antigenemia assay.

85 Four commercial BG antigenemia assays are available (Fungitell, Fungitec-G,

86 Studies reporting the performance of BG antigenemia assays for the diagnosis of IFI (European Or

87 Two consecutive positive antigenemia assays have very high specificity, positive

88 Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients,

89 Plasma antigenemia at 2 weeks after inoculation (P < or = 0.002

90 0 (50%) of 20 patients with asymptomatic CMV antigenemia at different levels.

91 te form of the disease showed rapid falls in antigenemia, becoming antigen negative by week 14 (range

92 r individuals with asymptomatic cryptococcal antigenemia but had limited predictive value for CM or m

93 als with neurologic symptomatic cryptococcal antigenemia but negative cerebral spinal fluid (CSF) stu

94 Prevalence of antigenemia by village ranged from 61.7% to 98.2% and di

95 Pre-emptive prophylaxis based on CMV antigenemia can effectively target the patients for CMV

96 splantation, preceding detection of CMV pp65 antigenemia, CD4 T-cell counts lower than 50 cells/mm(3)

97 ALB MDA on clearance of circulating filarial antigenemia (CFA) and microfilaremia.

98 oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients.

99 conventional cell culture (TC-CPE), the CMV-antigenemia (CMV-Ag) assay, one or more in-house CMV nes

100 el of CCIC in patients with asymptomatic CMV antigenemia, CMV pneumonia with or without copathogen, o

101 levels of serum CrAg and longer duration of antigenemia compared with the control patients.

102 ill significantly higher among patients with antigenemia count >11 leukocytes (adjusted RR = 4.9, 95%

103 of CMV disease compared to patients with an antigenemia count < or =11 leukocytes (RR = 7.3, 95% con

104 rtional hazards model, patients with a first antigenemia count of >11 leukocytes had a significantly

105 tive recipients were treated only when their antigenemia count reached a threshold of > or =100 posit

106 Cryptococcal antigenemia (CrAg+) in the absence of CM can represent e

107 s and asymptomatic, subclinical cryptococcal antigenemia (CRAG+) is unknown.

108 ed pregnant women and their newborns, clears antigenemia, crosses the placenta, and exhibits pharmaco

109 Duration of antigenemia decreased in 5 of 7 treated monkeys, 2 havin

110 al fungal pulmonary burden and galactomannan antigenemia demonstrated persistent infection, despite t

111 ith a high dose of AAV-HBV could not control antigenemia despite initially functional CD8+ T cell res

112 on-Hodgkin's lymphoma, cytomegalovirus (CMV) antigenemia, diabetes active at the time of the IFI, and

113 Antigenemia-directed valganciclovir as preemptive therap

114 The RRV 50% antigenemia dose was 1.8 x 10(3) PFU, and the 50% diarrh

115 ther rotavirus infection was associated with antigenemia during a major outbreak of gastroenteritis i

116 Elevated p24 antigenemia during the first 6 months of life correlates

117 Cryptococcal antigenemia encompasses a spectrum of conditions from pr

118 y dose of HBIg reduces the recurrence of HBs antigenemia, even in patients with indices of active vir

119 acute respiratory infection for cryptococcal antigenemia, even in the absence of meningitis.

120 In our analysis, antigenemia exhibited 85.8% sensitivity and 98.6% specif

121 ns were tested for CMV infection by (i) pp65 antigenemia expression in leukocytes, (ii) the Digene Hy

122 ld be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or continue to increase af

123 f CMV-specific immune reconstitution and CMV antigenemia following SCT.

124 for this finding is the persistence of HRP2 antigenemia following treatment of an acute infection.

125 to assess accuracy of 1,3-beta-d-glucan (BG) antigenemia for diagnosis of IAC.

126 ds as the primary risk factor for increasing antigenemia: for increases greater than or equal to twic

127 More patients in the antigenemia-ganciclovir group developed CMV disease befo

128 andomized at engraftment to receive placebo (antigenemia-ganciclovir group) or ganciclovir (ganciclov

129 ients with CMV disease before day 100 in the antigenemia-ganciclovir group, 10 (8.8%) had disease bef

130 oat of 29 patients, 14 of whom received pp65 antigenemia-guided early ganciclovir treatment and 15 of

131 In the 14 patients who received pp65 antigenemia-guided early treatment, the incidence of PBL

132 who received prophylactic ganciclovir versus antigenemia-guided pre-emptive therapy.

133 e found that individuals who experienced CMV antigenemia had lower tumor necrosis factor-alpha (TNF-a

134 ity of molecular diagnostic techniques (PCR, antigenemia) has resulted in our ability to detect viral

135 endently associated with hepatitis B surface antigenemia (hazard ratio [HR] 9.7, 95% confidence inter

136 7.3% and 8.3% respectively, with the rate of antigenemia (HCV antigen/anti-HCV) being 48.1%.

137 g individuals with asymptomatic cryptococcal antigenemia, higher GXMGal-IgG trended toward higher sur

138 50 of 51) of CMV-positive (cell culture- and antigenemia immunofluorescence [AG-IFA]-positive) clinic

139 e immunodiffusion tests detected P.marneffei antigenemia in 10 (58.8%) of 17 patients, whereas the la

140 hereas the latex agglutination test detected antigenemia in 13 (76.5%) of the 17 patients.

141 ay resulted in earlier detection compared to antigenemia in a time-to-event analysis of 42 CMV-seropo

142 into the bloodstream of mice to simulate the antigenemia in cryptococcosis, inhibits PMN accumulation

143 d symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons include

144 <=1:10 more frequently represented isolated antigenemia in HIV-positive than non-HIV, immunocompromi

145 e P101K substitution resulted in reduced NS1 antigenemia in mice, and this was associated with reduce

146 n detection was used to probe for SARS-CoV-2 antigenemia in plasma, and immune responses were charact

147 s (preferably) seroprevalence or (otherwise) antigenemia in the general population could be a key ing

148 cy virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal ampho

149 st's innate immune system and persistent BDG antigenemia, in the absence of IFD, can result in delete

150 Among the 47 patients with antigenemia increases greater than or equal to twice the

151 sment of viremia and daily assessment of NS1 antigenemia indicated balapiravir did not measurably alt

152 ion of L-FMAU significantly reduced viremia, antigenemia, intrahepatic WHV replication, and intrahepa

153 and people have demonstrated that rotavirus antigenemia is a common event during natural infection.

154 Preemptive therapy guided by pp65 antigenemia is a useful and cost effective strategy for

155 t MIS-C patients, suggesting that persistent antigenemia is not a common contributor to MIS-C pathoge

156 BG antigenemia is superior to Candida score and colonizatio

157 rtality in adults with HIV with cryptococcal antigenemia is unknown.

158 The CMV Brite antigenemia kit was compared with culture and an establi

159 Biotest CMV Brite and the Bartels/Argene CMV Antigenemia kits.

160 These findings in antigenemia largely parallel previous observations for G

161 The mean decline in the antigenemia level after initiation of valganciclovir and

162 The median reduction in antigenemia level with oral ganciclovir was 55% at week

163 y with R-/D+ CMV serostatus and baseline CMV antigenemia level, regardless of the study group.

164 eek 1, 93% by week 2, and 100% by week 4 had antigenemia levels below the baseline after oral gancicl

165 associated with rising cytomegalovirus (CMV) antigenemia levels during preemptive therapy among stem

166 Overall, rising antigenemia levels were not correlated with CMV disease.

167 eveloped during therapy, however, had rising antigenemia levels.

168 cted animals showed an early spike in plasma antigenemia, maintained high virus burdens, and had sign

169 ther study is warranted to determine whether antigenemia may aid individualized assessment of active

170 We describe how CMV antigenemia may be accurately detected by means of human

171 Thus, quantitative CMV pp65 antigenemia may be useful in guiding antiviral treatment

172 ata suggest that persistent SARS-CoV-2 spike antigenemia may contribute to multisystem inflammatory s

173 l three methods, including 2 with high-grade antigenemia (more than three positive cells in duplicate

174 Nucleocapsid antigenemia (N-Ag) was measured in RT-qPCR-positive resi

175 lasmodium falciparum HRP-2 (PfHRP-2)-related antigenemia (n=6121) following vitamin A supplementation

176 here were 122 samples that were PCR positive-antigenemia negative (specificity, 93%).

177 samples compared to 121 of 122 PCR positive-antigenemia negative samples (P < 0.001).

178 Twenty-three patients remained antigenemia negative throughout the monitoring period, n

179 of three patients with CMV disease who were antigenemia negative were detected by plasma PCR prior t

180 of the 15 patients (242 specimens) who were antigenemia negative were positive for CMV DNA by PCR, a

181 itive-PCR negative) and all 57 (PCR positive-antigenemia negative) could be confirmed at different ti

182 Of 50 patients without CMV antigenemia, none developed CMV disease.

183 Antigenemia occurred in 26 patients (38.8%) a median of

184 ive liver transplant recipients studied, CMV antigenemia occurred in 31% (22 of 72).

185 Antigenemia occurred in 9.3% of patients with non-SCT (n

186 Antigenemia occurred sporadically at low levels (< 5 pos

187 patients who presented with or progressed to antigenemia of > 5 positive cells/slide developed fatal

188 In patients with antigenemia of 3 or more positive cells in 2 slides and/

189 or causing false-positive galactomannan (GM) antigenemia of Plasma-Lyte hydration solution.

190 Thus, the impact of HIV antigenemia on B cells and Tfh cell interactions warrant

191 CMV-related death among patients with rising antigenemia on preemptive therapy.

192 assay was positive less frequently than the antigenemia or Amplicor assays.

193 After 3 months, continued detection of pp65 antigenemia or CMV DNA in plasma or peripheral blood leu

194 nfirmed CMV disease or CMV infection by pp65 antigenemia or CMV DNA PCR compared to maribavir patient

195 ase, nor posttransplantation cytomegalovirus antigenemia or cytomegalovirus disease had statistically

196 say was more likely to be positive at higher antigenemia or viral load levels.

197 immunological mediators that clear rotavirus antigenemia or viremia remain undefined.

198 genetics altered the occurrence of rotavirus antigenemia or viremia.

199 tion (AR) (p = 0.005), cytomegalovirus (CMV) antigenemia (p = 0.005) and lower respiratory tract infe

200 seropositive recipients), trends to less CMV antigenemia (P =.11), viremia (P =.16), and disease (P =

201 al burden (P</=.05), and serum galactomannan antigenemia (P</=.01), compared with either agent alone.

202 CMV DNA (as detected by PCR), but not antigenemia, persisted in patients who later developed r

203 ly treatment, the incidence of PBL PCR, pp65 antigenemia, plasma PCR, and viremia before day 100 was

204 onwide HIV survey and assayed for Plasmodium antigenemia, Plasmodium DNA, and IgG against Plasmodium

205 Twenty-three patients were antigenemia positive during the monitoring period, 12 of

206 uld be detected by other methods in 15 of 29 antigenemia positive-PCR negative samples compared to 12

207 On a per-subject basis, 21 of 25 patients (antigenemia positive-PCR negative) and all 57 (PCR posit

208 Asymptomatic cryptococcal antigenemia (positive blood cryptococcal antigen [CrAg])

209 There were 14 antigenemia-positive patients, 8 of whom developed activ

210 e values compared to antigenemia: 122 of 151 antigenemia-positive samples were detected (sensitivity,

211 ain reaction (qPCR) or phosphoprotein (pp65) antigenemia (pp65emia) for starting preemptive therapy h

212 demonstrated rapid disease, with progressive antigenemia preceding early deaths 90-96 days after inoc

213 ighly correlated with the seroprevalence and antigenemia prevalence at the moment of scale-down, or 1

214 e informative predictor of new VL cases than antigenemia prevalence.

215 d on population-based surveys of antibody or antigenemia prevalence.

216 therapy with ganciclovir after detection of antigenemia prevented all but one case of CMV disease pr

217 tiviral therapy instituted upon detection of antigenemia prevented tissue invasive CMV in both gancic

218 Untreated low-grade antigenemia progressed to CMV disease in 19% of patients

219 ctively for CMV infection (quantitative pp65 antigenemia, quantitative CMV-DNA, blood culture), T-cel

220 h or without SCT, Asians had the highest CMV antigenemia rates and burdens, followed by blacks, Hispa

221 ng the allogeneic SCT recipients, higher CMV antigenemia rates were also associated with female sex,

222 negative CMV antigenemia and resumed only if antigenemia recurred.

223 n, posaconazole and itraconazole resolved GM antigenemia, reduced residual fungal burden, and improve

224 gher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%

225 ithholding prophylaxis in the absence of CMV antigenemia, reliably identified patients in whom no pro

226 ng SHIV infection, a period of intense viral antigenemia, representation of various V(H) families inc

227 Clearance of antigenemia required lymphocytes, but neither T nor B ly

228 Q-PCR results were positive earlier than antigenemia results in 30 (77%) of 39 episodes detected

229 discontinuing ganciclovir based on negative antigenemia results in more CMV disease by day 100 than

230 Rotavirus antigens (antigenemia), RNA, or infectious virus (viremia) has bee

231 parasitemia (RR=0.46, 95% CI=0.39-0.54) and antigenemia (RR=0.23, 95% CI=0.17-0.29).

232 Thus, antigenemia sensitively and specifically marks acute SAR

233 e that even in the setting of low plasma HIV antigenemia, similar to what a vaccine can potentially a

234 s and was weakly associated with hepatitis B antigenemia, suggesting that persistence of HPV infectio

235 Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clin

236 of cytomegalovirus (CMV) infection using the antigenemia test has been used to monitor CMV infection

237 as an accurate and robust alternative to the antigenemia test to predict CMV disease and to monitor e

238 PCR and antigenemia test values decreased with anti-CMV therapy.

239 We compared results of the pp65 CMV antigenemia test with quantitative touch-down polymerase

240 ght laboratory assays, viz., the pp65 direct antigenemia test, a quantitative cytomegalovirus (CMV)-s

241 with a greater sensitivity than the standard antigenemia test.

242 outine preemptive therapy guided by the pp65 antigenemia test.

243 4 samples for blood culture, 290 samples for antigenemia testing, and 432 samples for PCR.

244 with 48, 99, 85, and 98%, respectively, for antigenemia testing, and 8, 100, 100, and 97%, respectiv

245 serial cytomegalovirus (CMV) blood culture, antigenemia testing, and qualitative and quantitative pl

246 emia weekly; those with positive findings on antigenemia tests were treated with intravenous ganciclo

247 id tumors had a significantly higher rate of antigenemia than those with myeloid tumors (13.6% versus

248 Among the 808 patients with antigenemia, the circulating peak CMV burden was signifi

249 There was a high correlation between antigenemia values and HCMV loads as determined by the T

250 Antigenemia values of 0, 1 to 10, 11 to 100, 101 to 1,00

251 Corresponding to antigenemia values of 1 to 2, 10, and 50 positive cells

252 Level of antigenemia varied inversely with survival.

253 r in P. falciparum infections with confirmed antigenemia versus those in clinical specimens with no a

254 These findings indicate that antigenemia/viremia occurs routinely in rotavirus infect

255 6- 37.8%) via RDT according to DHS, and HRP2 antigenemia was 38.3% (36.7-39.9%) by NAIIS DBS.

256 Antigenemia was associated positively with age in villag

257 In multivariable models, CMV pp65 antigenemia was associated with a decreased risk of rela

258 In univariate analyses, p24 antigenemia was associated with more-rapid progression t

259 Antigenemia was common in this outbreak and might provid

260 Rising antigenemia was confirmed by polymerase chain reaction f

261 Antigenemia was determined in 1322 persons by means of t

262 igh-dose steroids, low-level subclinical CMV antigenemia was found to stimulate both CD4+ and CD8+ fu

263 Antigenemia was higher in seronegative individuals and i

264 incidence of CMV infection based on CMV pp65 antigenemia was lower in each of the respective maribavi

265 Antigenemia was monitored weekly after liver transplanta

266 However, CMV antigenemia was more sensitive than culture at all time

267 In contrast, more effective control of antigenemia was observed following combination therapy,

268 Antigenemia was observed with homologous and heterologou

269 996 and 2004, surveillance testing using CMV antigenemia was performed at weeks 2, 4, 6, 8, 10, 12, a

270 fidence interval [CI]) clearance time of NS1 antigenemia was shorter in the ivermectin group (71.5 [9

271 Human cytomegalovirus antigenemia was the only variable assessed that was asso

272 Man CMV quantitative PCR (QPCR) with the CMV antigenemia was undertaken.

273 atients were prospectively monitored for CMV antigenemia weekly; those with positive findings on anti

274 ior to CMV exposure) on the incidence of CMV antigenemia were determined; and the CMV burdens were qu

275 CD4+ cell counts and antigenemia were measured throughout infection.

276 Alternatively, if antigenemia were monitored serially after transplant, th

277 atients, the highest levels and frequency of antigenemia were observed in samples from acute SARS-CoV

278 Surveillance cultures for CMV pp65 antigenemia were performed in all patients at weeks 2, 4

279 Patients with CMV antigenemia were randomized into two study groups.

280 Twenty-two patients with asymptomatic antigenemia were randomized to two study groups.

281 Cryptococcomas and serum antigenemia were slow to resolve.

282 eatures of reactivated cytomegalovirus (CMV) antigenemia were studied among 4,382 cancer patients who

283 allograft recipients, 119 patients with CMV antigenemia were studied.

284 CMV isolates obtained at the time of rising antigenemia were susceptible to ganciclovir, indicating

285 G4) levels (P = 0.0035) were associated with antigenemia, whereas microfilaremia was associated with

286 These findings suggest that the presence of antigenemia, which is an indicator of current active inf

287 positive by PBL PCR, plasma PCR, and/or pp65 antigenemia while receiving ganciclovir; 3 (20%) had bre

288 7/59) of the patients from 2001 to 2004 with antigenemia who received valganciclovir as preemptive th

289 participants (5%) had isolated cryptococcal antigenemia with a negative CSF CRAG and culture, of who

290 Cryptococcal antigenemia with meningitis symptoms was the third most

291 201) had neurologic symptomatic cryptococcal antigenemia with negative CSF CrAg.

292 roup, the association of hepatitis B surface antigenemia with TCC exit site infection was dependent o

293 r, and clinical implications of cryptococcal antigenemia within this spectrum.

294 (n = 114) was given ganciclovir for CMV pp65 antigenemia without prior acyclovir, and group 3 (n = 13